Journal of Clinical Endocrinology & Metabolism, Vol 81, 914-918, Copyright © 1996 by Endocrine Society

ARTICLES

Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression

F Cordido, R Peino, A Penalva, CV Alvarez, FF Casanueva and C Dieguez
Hospital J. Canalejo, School of Medicine, Santiago de Compostela University, Spain.

GH secretion in response to provocative stimuli is blunted in obese patients. On the other hand, increases in plasma free fatty acids (FFA) inhibit the GH response to a variety of stimuli, and FFA levels in plasma are increased with obesity. To ascertain whether FFA might be responsible for the GH secretory alterations of obesity, we studied spontaneous and stimulated GH secretion in 31 obese patients after FFA reduction by acipimox, a lipid-lowering drug devoid of serious side- effects. Each subject underwent two paired tests. In one, acipimox was administered orally at a dose of 250 mg at -270 min and at a dose of 250 mg at -60 min; in the matched test, placebo was given at similar intervals. To induce GH release, three stimuli acting through different mechanisms were used: pyridostigmine (60 mg, orally, at -60 min), GHRH (100 micrograms, iv, at 0 min), and GHRH plus GH-releasing peptide (GHRP-6; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; both at a dose of 100 micrograms, iv, at 0 min). GH secretion was analyzed as the area under the secretory curve (AUC; mean +/- SE; micrograms per L/60 min). Acipimox pretreatment alone (n = 13) induced a large reduction in FFA levels compared with placebo treatment. The FFA reduction led to a slight GH rise (AUC, 123 +/- 47), not different from that in the placebo group (61 +/- 15). In the pyridostigmine-treated group (n = 6), the acipimox-pyridostigmine AUC (408 +/- 107) was significantly higher (P < 0.05) than that in the placebo-pyridostigmine group (191 +/- 25). Furthermore, the GHRH-mediated (n = 6) AUC of GH secretion in the placebo test (221 +/- 55) was tripled by FFA reduction due to acipimox, with an AUC of (691 +/- 134; P < 0.05). Even the most potent GH stimulus known to date, i.e. GHRH plus GHRP-6, was enhanced by FFA suppression. In fact, the placebo-GHRH-GHRP-6 AUC was 1591 +/- 349, lower (P < 0.05) than that in the acipimox-GHRH-GHRP-6 test (2373 +/- 242). The enhancing effects of FFA lowering on GHRH-mediated and GHRH- plus GHRP-6-mediated GH release were synergistic. These results indicate that in obese subjects, unlike normal weight subjects. FFA reduction per se does not stimulate GH secretion. A reduction in FFA with acipimox, however, increased pyridostigmine-. GHRH-, and even GHRH- plus GHRP-6-mediated GH release, suggesting that FFA reduction operates through a different mechanism from that of these three stimuli. The abnormally high FFA levels may be a contributing factor for the disrupted GH secretory mechanisms in obesity.

This article has been cited by other articles:

				G. Fanciulli, A. Delitala, and G. Delitala Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone Hum. Reprod. Update, May 1, 2009; 15(3): 341 - 358. [Abstract] [Full Text] [PDF]

				M. H. Vickers, P. L. Hofman, P. D. Gluckman, P. E. Lobie, and W. S. Cutfield Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1212 - E1219. [Abstract] [Full Text] [PDF]

				D. Glintborg, R. K. Stoving, C. Hagen, A. P. Hermann, J. Frystyk, J. D. Veldhuis, A. Flyvbjerg, and M. Andersen Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5605 - 5612. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Growth Hormone (GH) Responses to GH-Releasing Hormone-Arginine Testing in Human Immunodeficiency Virus Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 32 - 38. [Abstract] [Full Text] [PDF]

				P. Kok, M. M. Buijs, S. W. Kok, I. H. A. P. van Ierssel, M. Frolich, F. Roelfsema, P. J. Voshol, A. E. Meinders, and H. Pijl Acipimox enhances spontaneous growth hormone secretion in obese women Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R693 - R698. [Abstract] [Full Text] [PDF]

				M. Ozata, C. Dieguez, and F. F. Casanueva The Inhibition of Growth Hormone Secretion Presented in Obesity Is Not Mediated by the High Leptin Levels: A Study in Human Leptin Deficiency Patients J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 312 - 316. [Abstract] [Full Text] [PDF]

				L. Gianotti, S. Pivetti, F. Lanfranco, F. Tassone, F. Navone, E. Vittori, R. Rossetto, C. Gauna, S. Destefanis, S. Grottoli, et al. Concomitant Impairment of Growth Hormone Secretion and Peripheral Sensitivity in Obese Patients with Obstructive Sleep Apnea Syndrome J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5052 - 5057. [Abstract] [Full Text] [PDF]

				M. Maccario, F. Tassone, L. Gianotti, F. Lanfranco, S. Grottoli, E. Arvat, E. E. Muller, and E. Ghigo Effects of Recombinant Human Insulin-Like Growth Factor I Administration on the Growth Hormone (GH) Response to GH-Releasing Hormone in Obesity J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 167 - 171. [Abstract] [Full Text]

				P. Sytze van Dam, H. E. C. Smid, W. R. de Vries, M. Niesink, E. Bolscher, E. J. Waasdorp, C. Dieguez, F. F. Casanueva, and H. P. F. Koppeschaar Reduction of Free Fatty Acids By Acipimox Enhances the Growth Hormone (GH) Responses to GH-Releasing Peptide 2 in Elderly Men J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4706 - 4711. [Abstract] [Full Text]

				J. A. Kanaley, M. M. Weatherup-Dentes, E. B. Jaynes, and M. L. Hartman Obesity Attenuates the Growth Hormone Response to Exercise J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3156 - 3161. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				E. Arvat, R. Giordano, J. Ramunni, G. Arnaldi, A. Colao, R. Deghenghi, G. Lombardi, F. Mantero, F. Camanni, and E. Ghigo Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4207 - 4211. [Abstract] [Full Text]

				F. Cordido, T. Fernandez, T. Martinez, A. Peñalva, R. Peinó, F. F. Casanueva, and C. Dieguez Effect of Acute Pharmacological Reduction of Plasma Free Fatty Acids on Growth Hormone (GH) Releasing Hormone-Induced GH Secretion in Obese Adults with and without Hypopituitarism J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4350 - 4354. [Abstract] [Full Text]

				S. M. Shalet, A. Toogood, A. Rahim, and B. M. D. Brennan The Diagnosis of Growth Hormone Deficiency in Children and Adults Endocr. Rev., April 1, 1998; 19(2): 203 - 223. [Abstract] [Full Text]

				A. Leal-Cerro, L. M. Jimenez, R. Astorga, I. Fernandez-Lopez, C. Dieguez, and F. F. Casanueva Acute Pharmacological Reduction of Plasma Free Fatty Acids Enhances the Growth Hormone (GH)-Releasing Hormone-Mediated GH Secretion in Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3165 - 3168. [Abstract] [Full Text] [PDF]

				E. Ghigo, E. Arvat, J. Ramunni, A. Colao, L. Gianotti, R. Deghenghi, G. Lombardi, and F. Camanni Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing Peptide, in Normal Subjects and Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2439 - 2444. [Abstract] [Full Text] [PDF]

				F. R. Perez, X. Casabiell, J. P. Camina, J. L. Zugaza, and F. F. Casanueva cis-Unsaturated Free Fatty Acids Block Growth Hormone and Prolactin Secretion in Thyrotropin-Releasing Hormone-Stimulated GH3 Cells by Perturbing the Function of Plasma Membrane Integral Proteins Endocrinology, January 1, 1997; 138(1): 264 - 272. [Abstract] [Full Text] [PDF]